In This Article:
OneMedNet’s new iRWD™ platform customer impacts more than 150 million patients each year
MINNEAPOLIS, May 29, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (“RWD”), inclusive of electronic health records, laboratory results and medical imaging, is pleased to announce that it has entered into a non-exclusive three (3)-year Master Services Agreement (“MSA”) with an undisclosed U.S.-based medical technology company that affects more than 150 million patients worldwide annually.
Pursuant to the MSA, OneMedNet will utilize its proprietary iRWD™ platform to securely de-identify, search and curate current, regulatory-grade clinical data for the new customer, including its world-wide subsidiaries and affiliates, under a pre-established fee-for-service model.
"As medical device companies increasingly look to leverage the use of existing RWD, particularly medical imaging data, across many stages of development, from ideation up to and including post-market surveillance, there is growing industry awareness and adoption of our highly differentiated iRWD™ platform,” said Aaron Green, OneMedNet’s President and CEO. “By providing timely access to de-identified and hard-to-curate current clinical information to this global medical technology industry leader, our aim is to not only provide it with comprehensive, accurate, and much needed patient information, but also help improve its competitive positioning by enabling it better informed decision-making.”
About OneMedNet Corporation
OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of more than 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to meet the clinical requirements necessary across various domains, including but not limited to rare diseases, oncology, and cardiology. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.